Summary
Axon Enterprise, Inc. (formerly TASER International, Inc.) reported strong growth in its 2015 fiscal year, driven by significant expansion in its Axon segment (wearable cameras and cloud-based evidence management) and continued strength in its core TASER weapons business. The company's strategic focus on protecting life through its TASER devices and protecting truth with its Axon technologies is yielding positive results, with Axon segment bookings surging by 136.7% year-over-year. This growth is underpinned by increased investment in research and development and a strategic expansion of its sales force, particularly in international markets. Financially, the company demonstrated robust top-line growth, with net sales increasing by 20.3%. The TASER Weapons segment saw a 11.5% increase, largely due to the adoption of newer Smart Weapons like the X26P and X2. The Axon segment was the clear growth engine, with sales jumping 87.8%, fueled by the increasing adoption of on-officer cameras and the Evidence.com platform by law enforcement agencies. Despite rising operating expenses, particularly in R&D and sales/marketing to support growth initiatives, the company maintained net income at $19.9 million for both 2015 and 2014, showcasing improving operational efficiency and gross margins.
Financial Highlights
53 data points| Revenue | $197.89M |
| Cost of Revenue | $69.25M |
| Gross Profit | $128.65M |
| R&D Expenses | $23.61M |
| SG&A Expenses | $69.70M |
| Operating Expenses | $93.31M |
| Operating Income | $35.34M |
| Net Income | $19.93M |
| EPS (Basic) | $0.37 |
| EPS (Diluted) | $0.36 |
| Shares Outstanding (Basic) | 53.55M |
| Shares Outstanding (Diluted) | 54.64M |
Key Highlights
- 1Significant growth in the Axon segment, with net sales increasing by 87.8% year-over-year, driven by the adoption of on-officer cameras and Evidence.com.
- 2TASER Weapons segment showed solid performance with an 11.5% increase in net sales, primarily attributed to upgrades to newer Smart Weapons (X26P and X2).
- 3Axon segment bookings experienced a substantial increase of 136.7%, indicating strong future revenue potential for the company's digital evidence solutions.
- 4Increased investment in Research & Development, up 58.6% from the prior year, with a focus on new product development for both TASER weapons and the Axon platform.
- 5The company repurchased approximately 0.3 million shares of its common stock for $7.6 million during 2015, completing its previously authorized stock repurchase program.
- 6Despite increased operating expenses, net income remained stable at $19.9 million for both 2015 and 2014, indicating effective cost management alongside growth initiatives.
- 7International sales continue to grow, contributing 18.2% of total net sales in 2015, up from 16.1% in 2013, showing progress in global market penetration.